Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ANVS
- Price
- 3.06
- Stock movement up
- +0.18 (6.25%)
- Company name
- Annovis Bio Inc
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 79.91M
- Ent value
- 68.66M
- Price/Sales
- -
- Price/Book
- 6.07
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 554.61%
- 1 year return (CAGR)
- -41.38%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ANVS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 6.07 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 26.11M |
| EPS (TTM) | -1.26 |
| FCF per share (TTM) | -260.39 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -26.72M |
| Net income (TTM) | -24.88M |
| EPS (TTM) | -1.26 |
| EPS (1y forward) | -1.34 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.29M |
| Net receivables | 0.00 |
| Total current assets | 17.19M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 17.19M |
| Accounts payable | 2.11M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.73M |
| Total liabilities | 4.03M |
| Shareholder's equity | 13.16M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -24.98M |
| Capital expenditures (TTM) | 13.00 |
| Free cash flow (TTM) | -5.13B |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -189.15% |
| Return on Assets | -144.77% |
| Return on Invested Capital | -189.15% |
| Cash Return on Invested Capital | -38960.91% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.93 |
| Daily high | 3.19 |
| Daily low | 2.93 |
| Daily Volume | 713K |
| All-time high | 120.97 |
| 1y analyst estimate | 13.75 |
| Beta | 1.61 |
| EPS (TTM) | -1.26 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 23 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ANVS | S&P500 | |
| Current price drop from All-time high | -97.47% | -0.89% |
| Highest price drop | -98.99% | -19.00% |
| Date of highest drop | 17 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -97.12% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
79.91M
Marketcap category
Small-cap
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Employees
8
Website
Investor relations
-
SEC filings
CEO
Maria-Luisa Maccecchini
Country
USA
City
Berwyn
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page